Audit of Compliance to Remdesivir Prescription Recommendations

Abstract

Remdesivir was the first antiviral medication to treat patients with COVID-19 and speed up the recovery time of patients with the disease. There are several criteria which should be considered when starting remdesivir, and COVID-19 patients should be eligible to start the medication. Compliance with the remdesivir criteria was satisfactory upon the outcome of this audit; however, because remdesivir remains an unlicensed medicine, we must maintain the standards and assess patient eligibility for the medicine before and during treatment. The main factor that was not followed was that some patients who received remdesivir had it beyond 10 days of having symptoms, which needs to be addressed so as to ensure that we are using this medication properly.